Liraglutide Improved Cardiometabolic Parameters More in Obese than in Non-obese Patients with Type 2 Diabetes: A Real-World 18-Month Prospective Study
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Liraglutide Improved Cardiometabolic Parameters More in Obese than in Non-obese Patients with Type 2 Diabetes: A Real-World 18-Month Prospective Study
Authors
Keywords
-
Journal
Diabetes Therapy
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-02-15
DOI
10.1007/s13300-022-01217-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Filling the gap between Guidelines and Real World in the cardiovascular approach to the diabetic patients: the need for a call to action
- (2021) Francesco Maranta et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Randomized Clinical Trial or Real-World Evidence: How Historical Events, Public Demand, and the Resulting Laws and Regulations Shaped the Body of Medical Evidence
- (2021) John I. Mackowiak et al. JOURNAL OF ORTHOPAEDIC TRAUMA
- Promoting a Syndemic Approach for Cardiometabolic Disease Management During COVID-19: The CAPISCO International Expert Panel
- (2021) Wael Al Mahmeed et al. Frontiers in Cardiovascular Medicine
- Diabetes and the COVID-19 Pandemic: How Insights from Recent Experience Might Guide Future Management
- (2020) Anca Pantea Stoian et al. Metabolic Syndrome and Related Disorders
- GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art
- (2020) Michael A. Nauck et al. Molecular Metabolism
- Liraglutide Reduces Carotid Intima-Media Thickness by Reducing Small Dense Low-Density Lipoproteins in a Real-World Setting of Patients with Type 2 Diabetes: A Novel Anti-Atherogenic Effect
- (2020) Dragana Nikolic et al. Diabetes Therapy
- Adoption of the ADA/EASD guidelines in 10 Eastern and Southern European countries: Physician survey and good clinical practice recommendations from an international expert panel
- (2020) Maciej Banach et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Exenatide once-weekly improves metabolic parameters, endothelial dysfunction and carotid intima-media thickness in patients with type-2 diabetes: An 8-month prospective study
- (2019) Angelo Maria Patti et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial
- (2019) Christian Anholm et al. ATHEROSCLEROSIS
- GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms
- (2018) Manfredi Rizzo et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study
- (2018) Niina Matikainen et al. DIABETES OBESITY & METABOLISM
- Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2018) Melanie J. Davies et al. DIABETES CARE
- Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study
- (2016) Manfredi Rizzo et al. Cardiovascular Diabetology
- Excess Mortality among Persons with Type 2 Diabetes
- (2016) NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Plasma Apolipoprotein C-III Levels, Triglycerides, and Coronary Artery Calcification in Type 2 DiabeticsSignificance
- (2015) Arman Qamar et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes
- (2015) Melanie J. Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- (2015) Xavier Pi-Sunyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Plasma triglycerides predict ten-years all-cause mortality in outpatients with type 2 diabetes mellitus: a longitudinal observational study
- (2014) Maria-Agata Miselli et al. Cardiovascular Diabetology
- Resistin: An Inflammatory Cytokine. Role in Cardiovascular Diseases, Diabetes and the Metabolic Syndrome
- (2014) Nicola Abate et al. CURRENT PHARMACEUTICAL DESIGN
- Prevalence of dyslipidemia and associated risk factors in Turkish adults
- (2014) Fahri Bayram et al. Journal of Clinical Lipidology
- A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis
- (2014) Yuko Tashiro et al. PEPTIDES
- The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE−/− mouse model
- (2013) Tracey Gaspari et al. Diabetes & Vascular Disease Research
- Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society
- (2013) E. R. Seaquist et al. DIABETES CARE
- Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial
- (2013) K. Hermansen et al. DIABETES OBESITY & METABOLISM
- Predictors of Insulin Resistance in Patients With Obesity
- (2012) Mariusz Stępień et al. ANGIOLOGY
- Endothelial dysfunction and carotid lesions are strong predictors of clinical events in patients with early stages of atherosclerosis: a 24-month follow-up study
- (2010) Egle Corrado et al. CORONARY ARTERY DISEASE
- Chronic Administration of the Glucagon-Like Peptide-1 Analog, Liraglutide, Delays the Onset of Diabetes and Lowers Triglycerides in UCD-T2DM Rats
- (2010) B. P. Cummings et al. DIABETES
- Ethnic differences in serum lipoproteins and their determinants in South African women
- (2010) Julia H. Goedecke et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Atherogenic lipoprotein phenotype and LDL size and subclasses in drug-naïve patients with early rheumatoid arthritis
- (2009) Manfredi Rizzo et al. ATHEROSCLEROSIS
- GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice
- (2009) M. H. Noyan-Ashraf et al. DIABETES
- Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with Type 2 diabetes
- (2008) Kaspar Berneis et al. EXPERT OPINION ON PHARMACOTHERAPY
- Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome
- (2008) K. Berneis et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Atherogenic lipoprotein phenotype and LDL size and subclasses in patients with peripheral arterial disease
- (2007) Manfredi Rizzo et al. ATHEROSCLEROSIS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started